Plans For US Government To Negotiate Prices Not A Done Deal, Says AZ’s Dobber
Pharma Fears Price Controls
While Democrat politicians - and most voters- want to see drug pricing negotiations introduced in the US for the first time, pharma leaders believe a deal on out of pocket costs will be agreed instead.
You may also be interested in...
AstraZeneca is one of the sector’s top growth stories in 2021, but controversies around its COVID-19 vaccine continue to grab headlines, and Chinese price cuts bite.
Medicare Price Negotiation Lite? Congress Targets Post-Exclusivity Drugs, Preserves Launch Price Discretion
Legislative deal on drug pricing reform includes a version of US government price negotiation for a subset of Medicare drugs. Only 10 will be selected for negotiation the first year but some analysts believe as many as 100 could be subject to negotiation by 2030.
GSK now looks free to pursue its ‘Plan A’ for the consumer division, but activist investors may push for a new bidder to be found.